Latest Equities News

NH3 Clean Energy has made significant strides in its flagship WAH2 low-emission ammonia project, signing pivotal agreements on carbon capture and ammonia bunkering while strengthening its financial position.

First Au Limited has consolidated its flagship Victorian Goldfields Project with 100% ownership and is aggressively advancing its Nimba Gold Project in Liberia, supported by a $1.5 million capital raise and new drilling programs.

Mindax Limited reported a net cash outflow from operations of A$516,000 for the June quarter, ending with A$1.3 million in cash and recently secured an additional A$1.6 million through a share placement.

Zelira Therapeutics reports promising diabetic neuropathy study results with ZLT-L-007 surpassing Lyrica, while converting $3.25 million in notes to equity to bolster HOPE® 1 clinical development.

Enlitic reports a 48% revenue surge in Q2 FY25, secures a major $50 million partnership with GE HealthCare, and completes a $10 million equity raise, positioning itself for operational break-even by year-end.

Rewardle Holdings has reinforced its strategic position by increasing its stake in CloudHolter following a $100 million capital raise, while progressing towards ASX relisting after resolving financial reporting delays.

DMC Mining’s planned acquisition of the Firawa and Labé uranium projects in Guinea faces delays due to exploration license approvals, while the company’s cash reserves dwindle to just A$14,000.

Waratah Minerals has reported significant extensions of high-grade gold mineralisation at its Spur Gold-Copper Project, alongside promising porphyry copper-gold intersections at Breccia West. The company also secured $8.4 million in new equity to accelerate drilling activities.

Renegade Exploration has acquired four promising projects in Nevada's Walker Lane trend, revealing impressive high-grade gold and silver samples, while advancing its Yukon and Australian assets amid a recent $1.8 million capital raise.

Orion Minerals reported significant cash outflows in its June 2025 quarter, with liquidity stretched and financing facilities nearly maxed out. The company is pursuing a $5.8 million capital raising to support ongoing operations following recent feasibility study completions.

Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.

Austral Gold’s Q2 2025 report reveals a production decline at its flagship Guanaco Mine alongside rising costs, while refurbishment at its Casposo Plant advances on schedule for a second-half restart.